Application of nanosonosensitizer materials in cancer sono-dynamic therapy

Hu, Chaotao; Hou, Biao; Xie, Songlin

doi:10.1039/d2ra03786f

Cited by 27 publications

(16 citation statements)

References 145 publications

(206 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the introduction of auxiliary nanoparticles in the sonosensitizer system has improved the sensitivity of sonodynamic therapy to some extent, the clinical application of this composite system is limited by the poor stability, complex process and high cost. 13 Therefore, it is extremely challenging to develop a new type of sonosensitizer to solve the above problems. Recently, the sonodynamic characteristics of porphyrin-based MOF materials have also been developed.…”

Section: Sonosensitizersmentioning

confidence: 99%

See 1 more Smart Citation

Ultrasound nanomedicine and materdicine

Wang

Chang

et al. 2023

J. Mater. Chem. B

View full text Add to dashboard Cite

show abstract

Section: Sonosensitizersmentioning

confidence: 99%

“…Up to now, most research supports that US-related therapy produces a synergistic effect to cause cell death through multiple mechanisms, including US cavitation effect, ROS effect and US-induced apoptosis. 13 Nevertheless, the verification of the definitive mechanism of US-related therapy needs more evidence.…”

Section: Us-related Therapeutic Mechanismsmentioning

confidence: 99%

Ultrasound nanomedicine and materdicine

Wang

Chang

et al. 2023

J. Mater. Chem. B

View full text Add to dashboard Cite

show abstract

“…Thus, it is important to choose good sonosensitizers for the most effective and safe SDT [141]. High bioavailability and good biocompatibility are required for the ideal sonosensitizer [144], thus, testing the biosafety of sonosensitizers in SDT is critical. In terms of in vitro cytotoxicity and in vivo toxicity, a cell proliferation activity test and mouse bladder section injury observation were performed.…”

Section: Sonodynamic Therapy Of Bladder Cancermentioning

confidence: 99%

Recent Progress in Nanomaterial-Based Biosensors and Theranostic Nanomedicine for Bladder Cancer

Song

Ding

et al. 2023

Biosensors

View full text Add to dashboard Cite

Bladder cancer (BCa) is one of the most expensive and common malignancies in the urinary system due to its high progression and recurrence rate. Although there are various methods, including cystoscopy, biopsy, and cytology, that have become the standard diagnosis methods for BCa, their intrinsic invasive and inaccurate properties need to be overcome. The novel urine cancer biomarkers are assisted by nanomaterials-based biosensors, such as field-effect transistors (FETs) with high sensitivity and specificity, which may provide solutions to these problems. In addition, nanomaterials can be applied for the advancement of next-generation optical imaging techniques and the contrast agents of conventional techniques; for example, magnetic resonance imaging (MRI) for the diagnosis of BCa. Regarding BCa therapy, nanocarriers, including mucoadhesive nanoparticles and other polymeric nanoparticles, successfully overcome the disadvantages of conventional intravesical instillation and improve the efficacy and safety of intravesical chemotherapy for BCa. Aside from chemotherapy, nanomedicine-based novel therapies, including photodynamic therapy (PDT), photothermal therapy (PTT), chemodynamic therapy (CDT), sonodynamic therapy (SDT), and combination therapy, have afforded us new ways to provide BC therapy and hope, which can be translated into the clinic. In addition, nanomotors and the nanomaterials-based solid tumor disassociation strategy provide new ideas for future research. Here, the advances in BCa diagnosis and therapy mentioned above are reviewed in this paper.

show abstract

“…Compared with PDT, SDT has deeper tissue penetration, making it more feasible for deep tumor therapy. 141 The rapid clearance and low accumulation of sonosensitizers limit the treatment effect of SDT. Therefore, it is important to improve the targeted and accumulated capacities of sonosensitizers in tumor sites.…”

Section: Sonodynamic Therapymentioning

confidence: 99%